Search results for "Hepatitis A"

showing 10 items of 60 documents

Low prevalence of anti-HCV antibody among Italian children

1994

The seroprevalence of anti-HCV antibody was studied among 2,749 children and teenagers (1,438 males and 1,311 females) living in Italy. Anti-HCV antibody testing was positive by both EIA and RIBA in ten (0.36%) subjects. The positivity rate increased with age, ranging from 0 among children less than 6 years of age to 0.8% among those aged 17-19 years chi 2 linear regression = 0.038). Anti-HCV prevalence ranged from 0.2% in northeastern regions and in Apulia to 0.6% in Sicily and Sardinia (p0.005), and no difference was seen between males (0.35%, C.I. 95%: 0.04-0.66) and females (0.38%, C.I. 95%: 0.04-0.66) (Fisher's exact test = 0.565). From these data it appears that in Italy HCV infection…

MaleMicrobiology (medical)Pediatricsmedicine.medical_specialtyAdolescentHepacivirusAnti hcv antibodyAge DistributionSeroepidemiologic StudiesPrevalenceHumansMedicineSeroprevalenceHepatitis AntibodiesSex DistributionChildbiologybusiness.industryGeneral MedicineHepatitis C AntibodiesExact testInfectious DiseasesItalyChild PreschoolPopulation SurveillanceLinear Modelsbiology.proteinFemaleAntibodybusinessDemographyInfection
researchProduct

Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-co…

2005

Objective The safety of a booster dose of a reduced-antigen-content tetanus–diphtheria–acellular pertussis (Tdap) vaccine was evaluated in adolescents previously vaccinated with five doses of acellular pertussis–containing vaccine. Study design Adolescents (n = 319) previously vaccinated with either 5 doses of diphtheria–tetanus–acellular pertussis (DTaP) (n = 193) or 4 doses of DTaP plus another acellular pertussis–containing vaccine received one dose each of Tdap and hepatitis A vaccine in a double-blinded, randomized, crossover trial. Rates of adverse events (AEs) after vaccination with Tdap versus hepatitis A and rates of local AEs among adolescents vaccinated with Tdap (sixth acellular…

MalePediatricsmedicine.medical_specialtyAdolescentWhooping CoughHepatitis A vaccineBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesSeverity of Illness IndexDouble-Blind MethodGermanymedicineHumansProspective StudiesAdverse effectChildWhooping coughImmunization ScheduleAntigens BacterialCross-Over StudiesTetanusDose-Response Relationship Drugbusiness.industryTetanusDiphtheriaIncidenceVaccinationHepatitis ADiphtheriamedicine.diseaseSurgeryVaccinationTreatment OutcomePediatrics Perinatology and Child HealthFemalebusinessFollow-Up StudiesThe Journal of pediatrics
researchProduct

Recent insights into the relationship between inflammatory liver diseases and atherosclerosis.

2011

Atherosclerosis is a dynamic process in the human body. Many studies have evaluated atherosclerosis and its relationship with other systems in the body. Our perception of its pathogenesis is evolving with the introduction of new players in the game. It is no longer possible to consider the atherosclerosis as an independent process, unaffected by the liver and its function. Although several tasks performed by the liver, such as lipid metabolism, have been implicated in the pathogenesis of atherosclerosis, the role of other disorders of the liver (autoimmune diseases, viral hepatitis, and cirrhosis) are not fully understood. In this review, the most commonly encountered inflammatory liver di…

MaleRiskHepatitis B virusCirrhosisInflammationHepacivirusBiologyGeneral Biochemistry Genetics and Molecular BiologyAutoimmune DiseasesHepatitisPathogenesisFibrosisPrevalencemedicineHumansInflammationHepatitisCholestasisLiver DiseasesResearchFatty liverLipid metabolismGeneral MedicineAtherosclerosismedicine.diseasehepatitis B hepatitis C hepatitis A inflammation fatty liver atherosclerosisFibrosisFatty LiverLiverImmunologyFemalemedicine.symptomViral hepatitis
researchProduct

Immunogenicity of reduced antigen content tetanus–diphtheria–acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pert…

2006

Three hundred and nineteen adolescents aged 10-12 years who had been previously vaccinated with five doses of acellular pertussis-containing vaccines received single doses of Tdap (reduced-antigen-content tetanus, diphtheria, acellular pertussis) and hepatitis A vaccines in a double-blind crossover trial. Long-term antibody persistence following vaccination with Tdap at pre-school age was similar to that following vaccination with DTaP (diphtheria-tetanus-acellular pertussis). After the sixth dose booster, Tdap induced a vigorous immune response, consistent with protection against diphtheria, tetanus and pertussis diseases.

MaleTime FactorsWhooping CoughHepatitis A vaccineImmunization SecondaryBooster doseDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesDouble-Blind MethodmedicineHumansChildWhooping coughAntigens BacterialHepatitis A VaccinesTetanusGeneral VeterinaryGeneral Immunology and MicrobiologyTetanusbusiness.industryImmunogenicityDiphtheriaPublic Health Environmental and Occupational HealthDiphtheriamedicine.diseaseAntibodies BacterialVaccinationInfectious DiseasesImmunizationImmunologyMolecular MedicineFemalebusinessVaccine
researchProduct

Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults.

2007

Response to hepatitis A and B vaccines has been reported to decline with age. This open, prospective, single-site study examined the long-term response to the combined hepatitis A/B vaccine Twinrix in 98 primary responders aged 45-67 years. Levels of antibody against hepatitis A virus (HAV) and hepatitis B surface antigen (HBs) were tested 30 months after initial vaccination. At this stage, all participants remained seropositive for anti-HAV and 70% for anti-HBs. A booster vaccination was offered to those who had responded to the first vaccination but then lost protective levels of anti-HBs. An anamnestic response was observed in all cases.

MaleTwinrixHepatitis A AntibodiesCohort StudiesMedicineHumansHepatitis B VaccinesProspective StudiesVaccines CombinedHepatitis B AntibodiesProspective cohort studyAgedHepatitis A VaccinesHepatitis B Surface AntigensGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryPublic Health Environmental and Occupational Healthvirus diseasesHepatitis AMiddle Agedmedicine.diseaseVirologydigestive system diseasesVaccinationClinical trialInfectious DiseasesImmunologyAntibody Formationbiology.proteinMolecular MedicineFemaleViral diseaseAntibodybusinessImmunologic MemoryCohort studyVaccine
researchProduct

Hepatitis C virus associated primary hepatocellular carcinoma in a noncirrhotic liver

1993

The case of a 71-year-old man with a primary hepatocellular carcinoma in a non-cirrhotic liver is reported. There were no risk factors of hepatocellular carcinoma (HCC)-like liver cirrhosis, alcohol drinking, tobacco smoking, exposure to vinyl chloride, thorotrast, aflatoxin or alpha 1-antitrypsin deficiency. Serologically, the patient was positive for antibodies to the hepatitis B virus (anti-HBc, anti-HBs) and for anti-hepatitis C virus (HCV) antibodies. Virologically, positive and negative strands of HCV RNA could be detected in the patient's serum and tumorous liver tissue by reverse transcription polymerase chain reaction as a sign of persistent HCV replication. Histologically, the HCC…

Malemedicine.medical_specialtyCarcinoma HepatocellularCirrhosisHepatitis C virusHepacivirusmedicine.disease_causeGastroenterologyViruschemistry.chemical_compoundRisk FactorsInternal medicineDrug DiscoverymedicineHumansHepatitis AntibodiesHepatitis B AntibodiesThorotrastGenetics (clinical)AgedHepatitis B virusbiologybusiness.industryIncidenceLiver NeoplasmsGeneral Medicinemedicine.diseaseHepatitis Cdigestive system diseaseschemistryHepatocellular carcinomabiology.proteinRNA ViralMolecular MedicineAntibodybusinessNodular regenerative hyperplasiaThe Clinical Investigator
researchProduct

Significance of IgG and IgM HCV antibody secretion in vitro in patients with chronic hepatitis C: correlation with disease activity and response to i…

1994

Hepatitis C virus antibodies are found in the serum of most patients with chronic hepatitis C. However, the significance of the humoral response is still uncertain. In this study, in vitro IgG and IgM anti-hepatitis C virus secretion by peripheral blood mononuclear cells of patients with chronic hepatitis C was analyzed. Peripheral-blood mononuclear cells from 21 of 36 patients (58.3%) secreted IgG anti-hepatitis C virus in vitro, as demonstrated with anti-hepatitis C virus—specific enzyme immunoassays and recombinant immunoblot assays. Ten of the 36 patients (27.8%) showed both IgG and IgM anti-hepatitis C virus core in vitro. In 9 of these 10 patients, IgM anti-hepatitis C virus was also …

Malemedicine.medical_specialtyHepatitis C virusHepacivirusInterferon alpha-2medicine.disease_causeVirus ReplicationPeripheral blood mononuclear cellVirusInterferonInternal medicinemedicineHumansHepatitis AntibodiesLymphocytesInterferon alfaCells CulturedHepatitisHepatologybiologybusiness.industryInterferon-alphaAlanine TransaminaseHepatologyHepatitis C AntibodiesMiddle Agedmedicine.diseaseVirologyHepatitis CRecombinant ProteinsImmunoglobulin MLiverImmunoglobulin GImmunologyChronic Diseasebiology.proteinFemaleAntibodybusinessmedicine.drugFollow-Up StudiesHepatology (Baltimore, Md.)
researchProduct

The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP.

2012

Blockade of the renin-angiotensin-aldosterone system (RAAS) affects both the glomerulus and tubules. We aimed to investigate the effect of irbesartan on the tubular markers: urinary (u) neutrophil gelatinase associated protein (NGAL), Kidney injury molecule 1 (KIM1) and liver-fatty acid-binding protein (LFABP).A substudy of a double-masked, randomized, cross-over study including 52 patients with type 2 diabetes, hypertension and microalbuminuria. After 2 months washout of all antihypertensive medication except bendroflumethiazid, patients were treated in random order with irbesartan 300, 600 and 900 mg for 2 months.Urinary tubular markers at baseline and after each treatment period (ELISA),…

Malemedicine.medical_specialtyUrinary systemClinical BiochemistryUrologyRenal functionEnzyme-Linked Immunosorbent AssayType 2 diabetesurologic and male genital diseasesFatty Acid-Binding ProteinsDiabetic nephropathyRenin-Angiotensin SystemIrbesartanLipocalin-2Internal medicineDiabetes mellitusProto-Oncogene ProteinsmedicineHumansDiabetic NephropathiesHepatitis A Virus Cellular Receptor 1AgedMembrane Glycoproteinsurogenital systembusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseLipocalinsEndocrinologyKidney TubulesAlbuminuriaReceptors VirusMicroalbuminuriaFemalemedicine.symptombusinessmedicine.drugAcute-Phase ProteinsScandinavian journal of clinical and laboratory investigation
researchProduct

Baseline seroepidemiology of hepatitis A virus infection among children and teenagers in Italy.

1991

During the period from May 1987 through November 1989, the prevalence of antibodies to hepatitis A virus infection (anti-HAV) was assayed by the ELISA method in the serum samples of 5,507 (54% males, 46% females) apparently healthy subjects three to 19 years old in Italy. Subjects were selected by a systematic cluster sampling in five different geographical areas of Italy. The overall prevalence of anti-HAV was 9.5%; it increased from 2.3% among children three to five-years-old to 16.3% in teenagers 17 to 19 years old (p less than 0.001). A slight preponderance of females was observed (10% versus 9.1%), but the difference was not statistically significant. The prevalence was significantly h…

Microbiology (medical)AdultMalemedicine.medical_specialtyAdolescentEnzyme-Linked Immunosorbent AssayAntibodies ViralSerologyEpidemiologyMedicineHumansHepatovirusElisa methodChildHepatitisbusiness.industryHealthy subjectsGeneral MedicineHepatitis Amedicine.diseaseHepatitis a virusYoung ageInfectious DiseasesEl NiñoItalySocioeconomic FactorsChild PreschoolImmunologyFemalebusinessDemographyInfection
researchProduct

Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy.

2011

Recent studies have shown that both glomerular and tubulointerstitial damage are important factors in the pathophysiology and progression of diabetic nephropathy. To examine whether markers of tubular damage are useful in monitoring the progression of disease, we measured urinary levels of neutrophil gelatinase-associated lipocalin (NGAL), liver-fatty acid-binding protein (LFABP), and kidney injury molecule-1 (KIM-1) in a 3-year intervention study of 63 type 1 diabetic patients with kidney disease. The baseline mean glomerular filtration rate (GFR) was 87 ml/min per 1.73 m(2) and urinary albumin excretion 1141 mg/24 h. Patients with the highest compared with the lowest quartile of urinary N…

NephrologyAdultMalemedicine.medical_specialtyUrinary systemUrologyRenal functiontubule cellsFatty Acid-Binding ProteinsLosartanDiabetic nephropathyLipocalin-2Internal medicineDiabetes mellitusProto-Oncogene ProteinsMedicineHumansDiabetic NephropathiesHepatitis A Virus Cellular Receptor 1Type 1 diabetesKidneyMembrane Glycoproteinsbusiness.industrydiabetic nephropathyMiddle Agedmedicine.diseaseLipocalinsEndocrinologymedicine.anatomical_structureDiabetes Mellitus Type 1Nephrologydiabetes mellitusReceptors VirusFemalebusinessBiomarkersKidney diseaseAcute-Phase ProteinsGlomerular Filtration RateKidney international
researchProduct